CN1313081C - 含有胶体二氧化硅的缬无环鸟苷片剂 - Google Patents

含有胶体二氧化硅的缬无环鸟苷片剂 Download PDF

Info

Publication number
CN1313081C
CN1313081C CNB2003101029136A CN200310102913A CN1313081C CN 1313081 C CN1313081 C CN 1313081C CN B2003101029136 A CNB2003101029136 A CN B2003101029136A CN 200310102913 A CN200310102913 A CN 200310102913A CN 1313081 C CN1313081 C CN 1313081C
Authority
CN
China
Prior art keywords
tablet
valacv
filler
silica sol
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2003101029136A
Other languages
English (en)
Chinese (zh)
Other versions
CN1494898A (zh
Inventor
B·H·卡尔特尔
L·G·蒂尔曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768317&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1313081(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of CN1494898A publication Critical patent/CN1494898A/zh
Application granted granted Critical
Publication of CN1313081C publication Critical patent/CN1313081C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CNB2003101029136A 1995-01-20 1996-01-19 含有胶体二氧化硅的缬无环鸟苷片剂 Expired - Fee Related CN1313081C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9501127.6A GB9501127D0 (en) 1995-01-20 1995-01-20 Tablet
GB9501127.6 1995-01-20

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN96192661A Division CN1131026C (zh) 1995-01-20 1996-01-19 含有胶体二氧化硅的缬无环鸟苷片剂

Publications (2)

Publication Number Publication Date
CN1494898A CN1494898A (zh) 2004-05-12
CN1313081C true CN1313081C (zh) 2007-05-02

Family

ID=10768317

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB2003101029136A Expired - Fee Related CN1313081C (zh) 1995-01-20 1996-01-19 含有胶体二氧化硅的缬无环鸟苷片剂
CN96192661A Expired - Fee Related CN1131026C (zh) 1995-01-20 1996-01-19 含有胶体二氧化硅的缬无环鸟苷片剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN96192661A Expired - Fee Related CN1131026C (zh) 1995-01-20 1996-01-19 含有胶体二氧化硅的缬无环鸟苷片剂

Country Status (38)

Country Link
US (1) US5879706A (enExample)
EP (1) EP0806943B1 (enExample)
JP (1) JP3350055B2 (enExample)
KR (1) KR100412298B1 (enExample)
CN (2) CN1313081C (enExample)
AP (1) AP666A (enExample)
AT (1) ATE190483T1 (enExample)
AU (1) AU710823B2 (enExample)
BG (1) BG63187B1 (enExample)
BR (1) BR9606769A (enExample)
CA (1) CA2210891C (enExample)
CY (1) CY2182B1 (enExample)
CZ (1) CZ296514B6 (enExample)
DE (1) DE69607146T2 (enExample)
DK (1) DK0806943T3 (enExample)
EA (1) EA000276B1 (enExample)
EE (1) EE03336B1 (enExample)
ES (1) ES2145425T3 (enExample)
FI (1) FI119722B (enExample)
GB (1) GB9501127D0 (enExample)
GE (1) GEP20022752B (enExample)
GR (1) GR3033677T3 (enExample)
HU (1) HU226131B1 (enExample)
IL (1) IL116830A (enExample)
IN (1) IN181318B (enExample)
MY (1) MY126346A (enExample)
NO (1) NO311488B1 (enExample)
NZ (1) NZ298846A (enExample)
OA (1) OA10500A (enExample)
PL (1) PL185307B1 (enExample)
PT (1) PT806943E (enExample)
RO (1) RO118175B1 (enExample)
SK (1) SK282030B6 (enExample)
TR (1) TR199700657T1 (enExample)
UA (1) UA68325C2 (enExample)
UY (2) UY25774A1 (enExample)
WO (1) WO1996022082A1 (enExample)
ZA (1) ZA96448B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
CA2243237C (en) * 1996-01-19 2008-09-02 Glaxo Group Limited Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application
AR017512A1 (es) * 1997-08-22 2001-09-12 Smithkline Beecham Corp Tabletas de metilcelulosa rapidamente desintegrables para administracion por via oral y procedimiento para prepararlas
AR016827A1 (es) 1997-08-22 2001-08-01 Smithkline Beecham Corp PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
BR9916361A (pt) * 1998-12-18 2002-11-05 Abbott Lab Forma de dosagem de tabletes de liberação controlada, formulação de tablete de liberação controlada, composição granular para prensagem em uma forma de dosagem de tablete de liberação controlada, e, métodos para preparar uma composição granular, para preparar uma forma de dosagem de tabletes de liberação controlada de divalproex sódio e para tratar epilepsia
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
UA75135C2 (en) * 2001-05-01 2006-03-15 Pfizer Prod Inc Dry granulation method for manufacturing pharmaceutical composition containing tetrahydronaphthalene-2-ol derivative and low dosage tablet compositions
US7815936B2 (en) * 2001-10-30 2010-10-19 Evonik Degussa Gmbh Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
AU2002348022B2 (en) * 2001-11-05 2006-06-15 Glaxo Group Limited Anhydrous crystal form of valaciclovir hydrochloride
CA2465928C (en) * 2001-11-14 2010-01-19 Teva Pharmaceutical Industries Ltd. Synthesis and purification of valacyclovir
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
EP1517678A2 (en) * 2002-06-24 2005-03-30 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US20050051922A1 (en) * 2002-09-20 2005-03-10 Avinash Nangia Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same
WO2004035583A1 (en) * 2002-10-16 2004-04-29 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
US20040109889A1 (en) * 2002-12-04 2004-06-10 Bunick Frank J. Surface treatment composition for soft substrates
WO2004106338A1 (en) * 2003-05-30 2004-12-09 Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. Novel crystalline forms of valacyclovir hydrochloride
EP2014660A3 (en) * 2003-06-02 2009-07-15 Teva Pharmaceutical Industries Ltd Novel crystalline forms of valacyclovir hydrochloride
US7632521B2 (en) * 2003-07-15 2009-12-15 Eurand, Inc. Controlled release potassium chloride tablets
HUE044822T2 (hu) 2003-09-12 2019-11-28 Amgen Inc Cinakalcet HCl gyors feloldódású készítménye
DE10351448A1 (de) * 2003-11-04 2005-06-09 Bayer Healthcare Ag Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
EP1541133B1 (en) * 2003-12-09 2005-08-10 Helm AG Pharmaceutical formulation of valaciclovir
US7344907B2 (en) * 2004-11-19 2008-03-18 International Business Machines Corporation Apparatus and methods for encapsulating microelectromechanical (MEM) devices on a wafer scale
KR101116747B1 (ko) 2004-12-06 2012-02-22 에스케이케미칼주식회사 안정성이 개선된 말레인산 암로디핀 약제 조성물
DK1868579T3 (da) 2005-03-07 2011-01-10 Bayer Schering Pharma Ag Farmaceutisk sammensætning omfattende en omega-carboxyaryl sunstitueret diphenylurea til behandling af cancer
ATE546451T1 (de) * 2005-05-25 2012-03-15 Lilly Co Eli Cyclopropancarbonsäureester von acyclovir
EP1746098A1 (en) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
WO2007090595A1 (en) * 2006-02-06 2007-08-16 Fidia Pharmaceutici S.P.A. Solid formulations of valacyclovir hydrochloride
JP2009536165A (ja) * 2006-05-10 2009-10-08 エボニック デグサ ゲーエムベーハー 医薬組成物におけるロール圧縮された熱分解的に製造された二酸化ケイ素の使用
EP2037887B1 (en) * 2006-05-31 2010-09-15 Vertex Pharmaceuticals Incorporated Oral controlled release formulations of an interleukin-1 beta converting enzyme inhibitor
US20090291136A1 (en) * 2006-07-11 2009-11-26 Lek Pharmaceuticals D.D. Multiple Unit Tablets
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
ITRM20080027A1 (it) * 2008-01-18 2009-07-19 Maria Balestrieri Uso di aciclovir per il trattamento delle condilomatosi.
US20100124560A1 (en) * 2008-11-14 2010-05-20 Mcneil Ab Multi portion intra-oral dosage form and use thereof
DK2407166T3 (da) * 2009-03-13 2013-10-07 Toyama Chemical Co Ltd Tablet og granuleret pulver indeholdende 6-fluor-3-hydroxy-2-pyrazin-carboxamid
CH703348A1 (de) * 2010-06-29 2011-12-30 Mepha Gmbh Zusammensetzungen mit hohem Wirkstoffanteil an pharmazeutisch aktiven Substanzen.
GB2515486A (en) * 2013-06-24 2014-12-31 Kraft Foods R & D Inc Soluble Beverage Ingredients
KR101497508B1 (ko) * 2013-12-20 2015-03-03 한국유나이티드제약 주식회사 펠라고니움 시도이데스 추출물 및 규산 화합물을 포함하는 고형 제제 및 이의 제조 방법
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
WO2020049536A1 (en) * 2018-09-07 2020-03-12 Jubilant Generics Limited Pharmaceutical compositions of valacyclovir or its pharmaceutically acceptable salts thereof
CN110279667B (zh) * 2019-07-30 2023-02-10 珠海润都制药股份有限公司 一种盐酸伐昔洛韦片及其制备方法
EP4157221A4 (en) * 2020-06-01 2024-07-24 Shilpa Medicare Limited RAPIDLY DISPERSABLE PHARMACEUTICAL COMPOSITION CONTAINING CAPECITABINE
TWI884340B (zh) * 2020-12-01 2025-05-21 南韓商Ｌｇ化學股份有限公司 用於口服投予的包含１－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸之複合調製劑和製備彼之方法
CA3266275A1 (en) * 2022-08-31 2024-03-07 Astrazeneca Ab PHARMACEUTICAL FORMULATION

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0308065A2 (en) * 1987-08-15 1989-03-22 The Wellcome Foundation Limited Therapeutic nucleosides
WO1995005179A1 (en) * 1993-08-18 1995-02-23 The Wellcome Foundation Limited Therapeutic combination containing an anti-varicella zoster virus compound and lamotrigine
CN1131026C (zh) * 1995-01-20 2003-12-17 惠尔康基金会集团公司 含有胶体二氧化硅的缬无环鸟苷片剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1259924A (en) * 1985-03-25 1989-09-26 Wallace E. Becker Pharmaceutical tableting method
EP0349103B1 (en) * 1988-05-04 1992-11-25 Smith Kline & French Laboratories Limited Chewable tablet
ATE133068T1 (de) * 1991-01-30 1996-02-15 Wellcome Found Wasserlösliche tabletten
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0308065A2 (en) * 1987-08-15 1989-03-22 The Wellcome Foundation Limited Therapeutic nucleosides
WO1995005179A1 (en) * 1993-08-18 1995-02-23 The Wellcome Foundation Limited Therapeutic combination containing an anti-varicella zoster virus compound and lamotrigine
CN1131026C (zh) * 1995-01-20 2003-12-17 惠尔康基金会集团公司 含有胶体二氧化硅的缬无环鸟苷片剂

Also Published As

Publication number Publication date
IL116830A0 (en) 1996-05-14
JPH10512564A (ja) 1998-12-02
SK282030B6 (sk) 2001-10-08
BG101831A (en) 1998-04-30
NO973327L (no) 1997-09-16
IN181318B (enExample) 1998-05-09
CA2210891C (en) 2009-05-19
DK0806943T3 (da) 2000-07-24
CZ296514B6 (cs) 2006-03-15
HU226131B1 (en) 2008-05-28
EA199700123A1 (ru) 1997-12-30
DE69607146D1 (de) 2000-04-20
EP0806943A1 (en) 1997-11-19
EA000276B1 (ru) 1999-02-25
HK1002851A1 (en) 1998-09-25
ES2145425T3 (es) 2000-07-01
FI973062L (fi) 1997-09-18
WO1996022082A1 (en) 1996-07-25
AU4453496A (en) 1996-08-07
NO311488B1 (no) 2001-12-03
TR199700657T1 (xx) 1998-02-21
CN1179100A (zh) 1998-04-15
AP666A (en) 1998-08-24
ZA96448B (en) 1996-08-07
CY2182B1 (en) 2002-08-23
BG63187B1 (bg) 2001-06-29
DE69607146T2 (de) 2000-09-21
SK96497A3 (en) 1998-01-14
RO118175B1 (ro) 2003-03-28
GR3033677T3 (en) 2000-10-31
GB9501127D0 (en) 1995-03-08
FI973062A0 (fi) 1997-07-18
MY126346A (en) 2006-09-29
NZ298846A (en) 1998-06-26
IL116830A (en) 2000-02-29
AU710823B2 (en) 1999-09-30
UA68325C2 (en) 2004-08-16
EE03336B1 (et) 2001-02-15
AP9701057A0 (en) 1997-10-31
FI119722B (fi) 2009-02-27
UY25778A1 (es) 2000-08-21
PT806943E (pt) 2000-08-31
ATE190483T1 (de) 2000-04-15
KR100412298B1 (ko) 2004-04-21
CA2210891A1 (en) 1996-07-25
CN1131026C (zh) 2003-12-17
HUP9801872A2 (hu) 1999-10-28
OA10500A (en) 2002-04-10
PL185307B1 (pl) 2003-04-30
CN1494898A (zh) 2004-05-12
US5879706A (en) 1999-03-09
MX9705459A (es) 1997-10-31
UY25774A1 (es) 2000-10-31
KR19980701524A (ko) 1998-05-15
EP0806943B1 (en) 2000-03-15
NO973327D0 (no) 1997-07-18
JP3350055B2 (ja) 2002-11-25
HUP9801872A3 (en) 2001-02-28
GEP20022752B (en) 2002-08-26
PL321361A1 (en) 1997-12-08
CZ229297A3 (cs) 1998-02-18
BR9606769A (pt) 1997-12-30

Similar Documents

Publication Publication Date Title
CN1313081C (zh) 含有胶体二氧化硅的缬无环鸟苷片剂
CN1049893C (zh) 缬无环鸟苷盐酸盐及其制法和其制药应用
TWI321475B (en) Novel pharmaceutical formulations of modafinil
CN1297274C (zh) 药物组合物
JP2015091882A (ja) 被覆錠剤製剤
CN1240132A (zh) 控制释放制剂
CN87105828A (zh) 苏灵大或苏灵大钠和碱的速效组合物
JP4097698B2 (ja) 一日一回の投与による陰部ヘルペス治療用医薬の製造のためのバラシクロビールの使用
CN101073563A (zh) 一种含有右旋布洛芬和左旋西替利嗪的手性组合物及其缓速释双层片
CN1612873A (zh) 5－(4－(2－(n－甲基－n－(2－吡啶基)氨基)乙氧基)苄基)噻唑烷－2,4－二酮以及包含该化合物的药物组合物
CN1660105A (zh) 含有替加氟、吉莫斯特和氧嗪酸钾的口腔崩解片
CN101066267A (zh) 一种含有阿立哌唑微晶的固体口服药物组合物
CN106955273B (zh) 一种含有钠-葡萄糖协同转运蛋白2抑制剂的药物组合物
CN1281272C (zh) 干扰素阴道泡腾胶囊及制备方法
MXPA97005459A (en) Valaciclovir tablets containing silicon dioxide color
HK1002851B (en) Valaciclovir tablets containing colloidal silicon dioxide
CN1642549A (zh) 包含纳米颗粒形状的2－(4－乙氧基－苯基)－3－(4－甲磺酰基－苯基)－吡唑并[1, 5－b]哒嗪的药物组合物
CN1596951A (zh) 黄柏分散片及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070502

Termination date: 20110119